Geode Capital Management
BRTX icon

Geode Capital Management’s BioRestorative Therapies BRTX Stock Holding History

Geode Capital Management’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.7K Buy
223,083
+165,229
+286% +$106K ﹤0.01% 4268
2025
Q4 		$67.7K Buy
57,854
+2,585
+5% +$3.44K ﹤0.01% 4179
2025
Q3 		$79K Buy
55,269
+1,007
+2% +$1.56K ﹤0.01% 4184
2025
Q2 		$90.6K Sell
54,262
-5,735
-10% -$9.96K ﹤0.01% 4087
2025
Q1 		$107K Buy
59,997
+5,275
+10% +$10.1K ﹤0.01% 4014
2024
Q4 		$78.3K Sell
54,722
-984
-2% -$1.52K ﹤0.01% 4157
2024
Q3 		$96.9K Buy
55,706
+3,369
+6% +$5.55K ﹤0.01% 4112
2024
Q2 		$106K Buy
52,337
+11,880
+29% +$17.1K ﹤0.01% 4122
2024
Q1 		$55.8K Sell
40,457
-2,821
-7% -$4.34K ﹤0.01% 4295
2023
Q4 		$74K Hold
43,278
– – ﹤0.01% 4265
2023
Q3 		$77K Sell
43,278
-498
-1% -$1.26K ﹤0.01% 4318
2023
Q2 		$193K Buy
43,776
+30,078
+220% +$144K ﹤0.01% 4060
2023
Q1 		$46.6K Hold
13,698
– – ﹤0.01% 4536
2022
Q4 		$37K Buy
13,698
+1,385
+11% +$4.31K ﹤0.01% 4671
2022
Q3 		$39K Hold
12,313
– – ﹤0.01% 4811
2022
Q2 		$36K Buy
12,313
+1,404
+13% +$5.95K ﹤0.01% 4844
2022
Q1 		$57K Buy
+10,909
New +$47.1K ﹤0.01% 4782

Other funds holding BRTX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Geode Capital Management's BRTX Position: Q1 2026 in Review

Geode Capital Management increased its BioRestorative Therapies (BRTX) stake by 286% in Q1 2026, buying an estimated $106K and bringing the position to 223,083 shares worth $60.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4268.

Geode Capital Management first reported a position in BRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $193K in Q2 2023. 11 funds tracked by Wall St. Rank hold BRTX as of Q1 2026.

  • Geode Capital Management held 223,083 shares of BioRestorative Therapies worth $60.7K as of Q1 2026.
  • Geode Capital Management bought 165,229 BioRestorative Therapies shares in Q1 2026, an estimated $106K.
  • BioRestorative Therapies made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4268 holding.
  • Geode Capital Management first reported a position in BioRestorative Therapies in Q1 2022 and has held it in 17 quarters since.
  • Geode Capital Management's BioRestorative Therapies position peaked at $193K in Q2 2023.
  • 11 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.